kabutan

Pharma Foods International Co., Ltd.(2929) Summary

2929
TSE Prime
Pharma Foods International Co., Ltd.
646
JPY
-4
(-0.62%)
Apr 28, 3:30 pm JST
4.05
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
12.5
PBR
1.92
Yield
3.87%
Margin Trading Ratio
2.27
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
654 JPY 4.10 USD
Previous Close Apr 27
650 JPY 4.07 USD
High Apr 28, 9:00 am
658 JPY 4.12 USD
Low Apr 28, 3:24 pm
646 JPY 4.05 USD
Volume
246,700
Trading Value
0.16B JPY 1.00M USD
VWAP
647.94 JPY 4.07 USD
Minimum Trading Value
64,600 JPY 405 USD
Market Cap
0.02T JPY 0.12B USD
Number of Trades
267
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Slightly High
1-Year Average
451
1-Year High Sep 11, 2025
4,808
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 63,200 790,500 12.51
Apr 17, 2026 170,600 746,600 4.38
Apr 10, 2026 183,100 769,800 4.20
Apr 3, 2026 191,500 808,700 4.22
Mar 27, 2026 192,900 858,600 4.45
Company Profile
Pharma Foods International Co., Ltd. primarily sells functional food ingredients such as GABA and folic acid egg supplements. The company is also involved in the development of antibody-based pharmaceuticals.
Sector
Foods
Pharma Foods International Co., Ltd. engages in the research, development, and manufacturing of functional ingredients, health foods, and pharmaceuticals. The company operates a B2B business, supplying materials to food and pharmaceutical manufacturers as well as distributors. They offer ingredients such as Pharma GABA, which provides stress relief and blood pressure improvement functions. Additionally, the company develops and sells its own brand products both domestically and internationally. In their B2C business, Pharma Foods International directly sells supplements, quasi-drugs, and cosmetics containing their proprietary functional ingredients to consumers through mail order. The Biomedical division conducts drug discovery research and development targeting intractable diseases such as autoimmune disorders and fibrosis, while also providing contracted services like proteome analysis. Furthermore, the company has expanded into venture capital and investment businesses.